Trial Profile

An Exploratory Phase IIa Study to Investigate the Biological Activity of Oral FX125L in Adult Patients with Chronic Inflammatory Disease.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 01 Sep 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FX 125L (Primary)
Indications Asthma; Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis
Focus Adverse reactions; Biomarker; Therapeutic Use

Most Recent Events

26 Apr 2012 Official Title amended, primary endpoints added and planned number of patients (119) added as reported by European Clinical Trials Database.
26 Apr 2012 New source identified and integrated (European Clinical Trials Database: EudraCT2011-005036-26).
26 Apr 2012 Status changed from planning to recruiting as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com